Introduction
Methods
Statistical analysis
Results
Patient characteristics | Mean |
---|---|
Age in years (min–max) | 69.2 (20–94 years) |
Male (%) | 151/250 (60.4%) |
Female (%) | 99/250 (39.6%) |
Aneurysmatic aorta (%) | 112/250 (44.8%) |
Normal aorta (%) | 107/250 (42.8%) |
Atherosclerotic aorta (%) | 20/250 (8%) |
Dissected aorta (%) | 11/250 (4.4%) |
Post-intervention (%) | 9/250 (3.6%) |
Zone lengths and central luminal line distances in relation to JTSCPG guidelines
Central luminal line measurements | Male (n = 151) Mean in mm (SD) | Female (n = 99) Mean in mm (SD) | p value |
---|---|---|---|
Distance mid CFA–AB | 222 (30.3) | 202 (25.6) | 0.000 |
Distance AB–distal origin of distal RA (length zone III) | 103 (23.9) | 97 (21.9) | ns |
Distance distal RA–CT (length zone II) | 42 (10.0) | 42 (10.8) | ns |
Distance of CT–distal origin of LSA (length zone I) | 260 (30.0) | 242 (31.8) | 0.000 |
Distance mid CFA–mid zone III | 274 (28.0) | 251 (23.3) | 0.000 |
Distance mid CFA–mid zone II | 347 (30.8) | 320 (26.3) | 0.000 |
Distance mid CFA–mid zone I | 497 (39.3) | 462 (36.0) | 0.000 |
Aorta diameter mid zone III | 35 (20.9) | 27 (17.4) | 0.001 |
Aorta diameter mid zone II | 26 (6.4) | 23 (7.5) | 0.002 |
Aorta diameter mid zone I | 31 (7.6) | 29 (9.6) | ns |
JTSCPG guideline: introduction depths for zone III and I
Eliason’s adjustment of the JTSCPG guideline
ABO introduction depths | Zone III (cm) | Successful deployment (n) | Zone I (cm) | Successful deployment (n) | |
---|---|---|---|---|---|
JTSCPG | Female (n = 99) | 27 | 39/99 (39.4%) | 46 | 92/99 (92.9%) |
Male (n = 151) | 27 | 21/151 (13.9%) | 46 | 107/151 (70.9%) | |
Total (n = 250) | 60/250 (24.0%) | 199/250 (79.6%) | |||
Eliason | Female (n = 99) | 28 | 56/99 (56.6%) | 48 | 97/99 (98.0%) |
Male (n = 151) | 28 | 39/151 (25.8%) | 48 | 133/151 (88.1%) | |
Total (n = 250) | 95/250 (38.0%) | 230/250 (92.0%) | |||
Borger et al | Female (n = 99) | 30.8 | 75/99 (75.8%) | 51.9 | 97/99 (98.0%) |
Male (n = 151) | 33.1 | 113/151 (74.8%) | 55.4 | 150/151 (99.3%) | |
Total (n = 250) | 188/250 (75.2%) | 247/250 (98.8%) |
Borger: introduction depths for zone III and I
Variations and age
Age groups | 20–50 years (n = 29) | 51–70 years (n = 81) | 71–94 years (n = 140) | p valuea (1–2) | p valuea (1–3) | p valuea (2–3) |
---|---|---|---|---|---|---|
Distance mid CFA–ABb | 208 [197–222] | 215 [198–233] | 208 [191–232] | ns | ns | ns |
Distance AB– distal origin of distal RAb (length zone III) | 88 [80–102] | 96 [87–111] | 104 [-91–118] | ns | 0.000 | 0.049 |
Distance distal RA–CT (length zone II) | 44 [36–51] | 43 [38–47] | 40 [34–46] | ns | ns | ns |
Distance of CT–distal origin of LSAb (length zone I) | 237 [201–246] | 246 [235–272] | 259 [242–273] | 0.000 | 0.000 | 0.041 |
Distance mid CFA–mid zone IIIb | 251 [242–271] | 263 [246–282] | 264 [245–286] | ns | ns | ns |
Distance mid CFA—mid zone IIb | 319 [302–338] | 333 [317–354] | 338 [312–363] | 0.022 | 0.013 | ns |
Distance mid CFA—mid zone Ib | 454 [435–479] | 480 [461–512] | 487 [455–518] | 0.001 | 0.000 | ns |
Aorta diameter mid zone 3b | 17 [14–19] | 22 [17–34] | 37 [20–56] | 0.000 | 0.000 | 0.000 |
Aorta diameter mid zone 2b | 19 [17–23] | 23 [21–34] | 25 [22–28] | 0.000 | 0.000 | 0.000 |
Aorta diameter mid zone 1b | 23 [21–26] | 27 [26–30] | 30 [27–33] | 0.000 | 0.000 | 0.000 |
Correlations
Correlation of mid-sternum to zone I | Male | Female | P value |
---|---|---|---|
Proximal 1/3 of zone I | 94/151 (62.3%) | 62/99 (62.6%) | ns |
Middle 1/3 of zone I | 57/151 (37.7%) | 37/99 (37.4%) | ns |
Distal 1/3 of zone I | 0/151 (0%) | 0/99 (0%) | ns |
Relation between aortic and balloon diameters
Aortic occlusion balloon | Max inflation ∅ (mm] | Occlusion success zone III (%) | Occlusion success zone I (%) |
---|---|---|---|
REBOA Balloon® 15, REBOA Medical | 15 | 11/250 (4.4%) | 0/250 (0%) |
REBOA Balloon® 20, REBOA Medical | 20 | 86/250 (34.4%) | 7/250 (2.8%) |
Equalizer™ Occlusion Balloon Catheter 17–105, Boston Scientific | 20 | 86/250 (34.4%) | 7/250 (2.8%) |
Equalizer™ Occlusion Balloon Catheter 17–107, Boston Scientific | 27 | 150/250 (60.0%) | 85/250 (32.8%) |
Fogarty® Occlusion Catheter 62080814F, Edwards Lifesciences | 28 | 154/250 (61.6) | 107/250 (42.8%) |
LeMaitre® 2107–80 Aortic Occlusion Catheter, LeMaitre Vascular | 28 | 154/250 (61.6) | 107/250 (42.8%) |
Coda® 2–9.0–35-100–32, Cook Medical | 32 | 163/250 (65.2%) | 183/250 (73.2%) |
ER-REBOA™, Prytime Medical Devices | 32 | 163/250 (65.2%) | 183/250 (73.2%) |
Equalizer™ Occlusion Balloon Catheter 17–109, Boston Scientific | 33 | 167/250 (66.8%) | 198/250 (79.2%) |
Equalizer™ Occlusion Balloon Catheter 17–111, Boston Scientific | 40 | 183/250 (73.2%) | 227/250 (90.8%) |
Rescue balloon™ RB-167080-E, Tokai Medical Products | 40 | 183/250 (73.2%) | 227/250 (90.8%) |
Fogarty® Occlusion Catheter 62080822F, Edwards Lifesciences | 45 | 191/250 (76.4%) | 232/250 (92.8%) |
LeMaitre® 2107–81 Aortic Occlusion Catheter, LeMaitre Vascular | 45 | 191/250 (76.4%) | 232/250 (92.8%) |
Coda® 2–9.0–35-140–46, Cook Medical | 46 | 195/250 (78.0%) | 234/250 (93.6%) |
Reliant™ Stent Graft Balloon Catheter, Medtronic | 46 | 195/250 (78.0%) | 234/250 (93.6%) |
Q50® Plus Q50-65P, QXMédical (Merit Medical) | 50 | 199/250 (79.6%) | 239/250 (95.6%) |
Q50X™ Q50-65-Xa, QXMédical (Merit Medical) | 50 | 199/250 (79.6%) | 239/250 (95.6%) |